MONTREAL, CANADA--(Marketwired - April 24, 2013) - Paladin Labs Inc. (PLB.TO), a leading Canadian specialty pharmaceutical company, announced today the launch of AmnioSense, Canada's first and only over-the-counter amniotic fluid leak detection test.
AmnioSense is an easy-to-use and non-intrusive panty liner self-test that detects amniotic fluid leakage when women experience unidentified vaginal wetness during their pregnancy. Studies have shown that premature amniotic fluid leakage occurs in approximately 10% of pregnancies(1). If undetected, amniotic fluid leakage may lead to infections in the mother and fetus, and could result in a greater risk of premature delivery(1). Rapid diagnosis of amniotic fluid leakage is important for improving neonatal outcomes(2). Unfortunately, amniotic fluid leakage can be easily mistaken for urinary incontinence, an issue that affects 46% of women in the third trimester(3), thus the need for this diagnostic.
"We are excited to announce the launch of AmnioSense, an important addition to our growing women's health OTC portfolio." said Mark Beaudet, interim President and Chief Executive Officer of Paladin Labs Inc. "AmnioSense is a novel and reliable diagnostic test that will help pregnant women differentiate amniotic fluid from urine in just seconds and ensure that they are able to seek fast and appropriate treatment in the event of an amniotic fluid leak."
Paladin obtained the exclusive rights to market and sell AmnioSense (AL-SENSE OTC) in Canada, Latin America and Sub-Saharan Africa from Common Sense Limited in August 2011.
AmnioSense is an easy to use self-test that detects probable leakage of amniotic fluid by reacting to pH and ammonia levels. It is intended for pregnant women experiencing vaginal wetness.
About Paladin Labs Inc.
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB. For more information, please visit the Company's web site at www.paladinlabs.com.
This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Company's Annual Information Form for the year ended December 31, 2012. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly filings, annual report and Annual Information Form and other fillings found on SEDAR at www.sedar.com.
(1) Caughey, AB et al. Contemporary diagnosis and management of preterm premature rupture of membranes. Rev Obstet Gynecol, 2008;1(1):11-22.
(2) Medina, TM and Hill, D. Preterm premature rupture of membranes: diagnosis and management. Am Fam Physician, 2006;73(4):659-664.
(3) Wesnes SL et al. Urinary incontinence during pregnancy. Obstet Gynecol, 2007;109(4):922-928.